Navigation Links
Inverness Medical Innovations Announces Third Quarter 2008 Results
Date:10/29/2008

59,552) 155,349

Operating income (loss) 13,247 72,273 85,520

Interest and other income

(expense), net (24,752) 300( c ) (24,452)

Income tax (benefit)

provision (4,696) 26,018(g) 21,322

Equity earnings of

unconsolidated entities,

net of tax 3,150 237(b) 3,387

Net (loss) income $(3,659) $46,792 $43,133

Preferred stock dividends $(5,393) $(5,393)

Net (loss) income

available to common

stockholders - basic $(9,052) $37,740

Net (loss) income per

common share

Basic $(0.12) $0.48

Diluted $(0.12)(h) $0.46(i)

Weighted average common

shares - basic 77,995 77,995

Weighted average common

shares - diluted 77,995(h) 83,169(i)

Three Months Ended September 30, 2007

Non-GAAP

Non-GAAP Adjusted Cash

GAAP Adjustments Basis(a)

Net revenue $237,636 $- $237,636

Cost of revenue 127,338 (13,938)(b)(d)(e) 113,400

Gross profit 110,298 13,938 124,236

Gross margin 46% 52%

Operating expenses:

Research and development 20,530 (1,535)(b)( c )(d) 18,995

Purchase of in-process

research and development 169,000 (169,000)(f) -

Selling, ge
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
2. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
3. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
4. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
5. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
6. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
7. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
8. Inverness Medical Innovations Announces Second Quarter 2008 Results
9. Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008
10. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
11. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies Corp. ... developing first in class collagenase-based products marketed as ... in the U.S. and XIAPEX ® in ... from a randomized, double-blind Phase 2a study of ... edematous fibrosclerotic panniculopathy. The results showed that all ...
(Date:8/21/2014)... & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of JRC-LAMP-vax, ... Japanese red cedar pollen. Phase IC studies began this ... real solution to hay fever. , The Japanese red ... 35 million people in Japan. Mountain Cedar pollen wreaks ...
(Date:8/21/2014)... research group at the Institute for Molecular Medicine ... Stockholm, has developed a novel "man and machine" ... innovative diagnostic aid was described in PLOS ... method is based on computer vision algorithms similar ... with visualization of only the diagnostically most relevant ...
(Date:8/21/2014)... including DESY scientists has observed tiny quantum vortices in ... the journal Science that the exotic vortices ... It is the first time that the quantum vortices, ... what is known as superfluid helium, have been detected ... says Andrey Vilesov of the University of Southern California, ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Scientists observe quantum vortices in cold helium droplets 2
... VEENENDAAL, The Netherlands, June 2 ... today announced the creation,of an exclusive partnership and ... for an undisclosed sum. The two companies, headquartered ... the combination,will strengthen Nucletron,s position as global leader ...
... The American Institute of Aeronautics and Astronautics ... top emerging aerospace technologies. Developed by AIAA,s ... following: 1. "Greener Aviation" Technologies including emission ... the Federal Aviation Administration,s Continuous Low Emissions, Energy ...
... First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL , ... to treat Analysis results per FDA agreed upon Statistical Analysis Plan , ... Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021 ... Rate 37.1% vs. 14.3%; p=0.003 , ...
Cached Biology Technology:Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 2Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 3AIAA names top ten emerging aerospace technologies of 2009 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 3Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 4Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 5
(Date:8/21/2014)... Athens, Ga. An international team of scientists including researchers ... Brassica napus commonly known as canolain the journal ... of the plant, which is used widely in farming and ... and its native Europe, but the winter crop is increasingly ... for its naturally low levels of saturated fat and rich ...
(Date:8/21/2014)... significant reduction in smog-producing toxins in past decade, ... new study shows that while the Greater Toronto ... toxins that contribute to smog, the city continues ... pollution., Smog, which can cause or aggravate health ... is produced by a set of complex photochemical ...
(Date:8/21/2014)... American singles found that during sex with a ... On average, men experience orgasm 85.1 percent of ... difference. For women, however, orgasm occurrence is less ... of the time during sex with a familiar ... sexual orientation, with lesbian women experiencing orgasm more ...
Breaking Biology News(10 mins):Canola genome sequence reveals evolutionary 'love triangle' 2Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4
... A drug made from the saliva of the Gila ... food. Researchers at the Sahlgrenska Academy, University of Gothenburg, ... ceased their cravings for both food and chocolate. ... diabetes are offered a pharmaceutical preparation called Exenatide, which ...
... 15, 2012) The Mass. Eye and Ear Curing Kids ... help the brain locate sound, identify genes that cause congenital ... for childhood eye cancer. The 2011/2012 Curing Kids Fund grants ... Sense-sation! gala. This year,s grant recipients are: , ...
... are used in gardens, burned for heat and energy, and ... grass family that includes corn, sorghum and sugarcane. Two new, ... (an ornamental that likely is a parent of Miscanthus ... sequencing the M. sinensis genome. The studies reveal ...
Cached Biology News:Drugs from lizard saliva reduces the cravings for food 2Mass. Eye and Ear announces Curing Kids Fund grant recipients 2Maps of Miscanthus genome offer insight into grass evolution 2Maps of Miscanthus genome offer insight into grass evolution 3
This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: